GeneDx upgraded to Buy from Hold on growth outlook

 

• GeneDx (NASDAQ:WGS) was upgraded to Buy from Hold at Jefferies banking on the company's growth outlook following meetings with management in London.
• Despite a rocky start to the year, including a Q1 volume miss, analysts at Jefferies now see a clear path to recovery driven by strong growth in neonatal intensive care unit testing, new clinical indications, and improving cost efficiency.
• "Of course, it will take time to rebuild credibility, but reset valuation is compelling for one of the better growth stories in diagnostics with no competition," Tycho Peterson, analyst at Jefferies said.
• Jefferies has maintained its price target of $80. 

https://www.msn.com/en-us/money/markets/genedx-upgraded-to-buy-from-hold-on-growth-outlook/ar-AA1EtYPn